Clinical Trial Update: Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports completing the study investigating combining EPI-7386 with enzalutamide and androgen deprivation therapy in metastatic hormone-se…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• EPI-7386
• Xtandi (enzalutamide)

Snippet

Sponsor: Pedro Barata, MD, MSc | Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer | Phase 2 | Status: COMPLETED